Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAB-BX400
- Development stage
- Preclinical
- Lead developer
- Jacobio Pharmaceuticals Co., Ltd.
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JAB-BX400 is a preclinical-stage investigational antibody-drug conjugate (ADC) developed by Jacobio Pharma. It is an immune-stimulating ADC (iADC) that targets the human epidermal growth factor receptor 2 (HER2) and delivers a stimulator of interferon genes (STING) agonist as its payload. The design aims to selectively deliver the STING agonist into HER2-expressing tumor cells, thereby locally activating innate and adaptive antitumor immune responses while minimizing systemic immune-related toxicity. Preclinical studies have shown that JAB-BX400 is effective against DS8201-resistant tumor models and in "cold" tumors such as the SK-OV-3 xenograft model, which are typically less responsive to immunotherapy[2][4][5][6][7]. The drug barely releases free payload in plasma, reducing off-target effects and cytokine release compared to competitors[7]. An IND application for clinical trials is planned for 2024–2025[2].
- Other names
- HER2-STING iADCHER-2-STING iADCHER 2-STING iADC
02
Targets
STING (Stimulator of interferon genes protein)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on JAB-BX400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAB-BX400.